أخبار السوق

Official Partner ITBFX Start Trading

0 0 0

المصدر: Seeking Alpha وكالة أنباء

قبل شهر واحد

الأسهم أهمية متوسطة

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and Rezlidhia trials provide additional growth catalysts.

الرموز ذات الصلة 1

R RIGL RIGL

المصدر: Seeking Alpha

0 0 0

المصدر: Reuters وكالة أنباء

قبل شهر واحد

الأسهم أهمية متوسطة

Australia's Beach Energy swings to annual profit, shares slide on weak production outlook

Beach Energy posted an annual profit on Thursday, a sharp turnaround from a year-earlier loss, although shares of the Australian oil and gas producer slipped more than 6% as ‌investors focused on its soft production outlook.

الرموز ذات الصلة 1

B BCHEY BCHEY

المصدر: Reuters

0 0 0

المصدر: Accesswire وكالة أنباء

قبل شهر واحد

الأسهم أهمية متوسطة

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) supporting mFLUSIVA for adults 50 years of age and older.

الرموز ذات الصلة 1

M MRNA MRNA

المصدر: Accesswire

0 0 0

المصدر: Newsfile Corp وكالة أنباء

قبل شهر واحد

الأسهم أهمية متوسطة

Kingman Adopts Semi-Annual Financial Reporting

Vancouver, British Columbia--(Newsfile Corp. - August 5, 2026) - Kingman Minerals Ltd. (TSXV: KGS) (OTCQB: KGSSF) (FSE: 47A1) ("Kingman" or the "Company") announces that its Board of Directors has approved the Company's election to rely on Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the "Blanket Order") issued by the Canadian Securities Administrators ("CSA").

الرموز ذات الصلة 1

K KGS KGS

المصدر: Newsfile Corp

0 0 0

المصدر: 24/7 Wall Street وكالة أنباء

قبل شهر واحد

الأسهم أهمية متوسطة

From $100 to $2,021 in Five Years: How Daily-Reset Leverage Turns Trends Into Fortunes

Here is the number that should stop any leveraged ETF trader in their tracks: year to date through Tuesday's close, the GraniteShares 2x Long NVDA Daily ETF (NASDAQ:NVDL) is up 11.5%.

الرموز ذات الصلة 1

N NVDL NVDL

المصدر: 24/7 Wall Street

0 0 0

المصدر: GlobeNewsWire وكالة أنباء

قبل شهر واحد

الأسهم أهمية متوسطة

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed after repeated surprise unit handpiece sales underperformance and gradual revelations of excess customer inventory levels driven by repeated, late-quarter, bulk discounts. The lawsuit seeks to represent investors who purchased or otherwise acquired PROCEPT common stock between February 28, 2024 and February 25, 2026.

الرموز ذات الصلة 1

P PRCT PRCT

المصدر: GlobeNewsWire

0 0 0